• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
IL-1 Signaling Pathway in Oncology Drug Pipeline Update 2015 Product Image

IL-1 Signaling Pathway in Oncology Drug Pipeline Update 2015

  • ID: 1537329
  • January 2015
  • Region: Global
  • Bioseeker

The IL-1 signaling pathway activates the MAPK/JNK signaling modules. The MAPK pathway leads to activation of NFkB complex. As both IL-1 and TNF alpha stimulate the MAPK signaling module and activate NFkB, they are synergistic and complement each other's activity.

There are today 89 companies plus partners developing 78 IL-1 pathway targeting drugs in 331 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 53 drugs. Il-1 Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 89 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 85 out of the 88 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 28 classifications of molecular function and with pathway READ MORE >

Note: Product cover images may vary from those shown



Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Photocure ASA Roche Diagnostics Ltd. Abbott Laboratories Ltd. Pfizer, Inc. Novartis AG Becton, Dickinson and Company (BD)